Krebs Biochemicals and Industries Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 26, 2025

Krebs Biochemicals and Industries Limited held its 33rd Annual General Meeting on September 26, 2025, and all nine resolutions placed before shareholders were passed with the requisite majority. Key resolutions included adoption of the audited financial statements for FY ending March 31, 2025, re-appointment of two retiring directors (Mr. Avinash Ravi and Mr. Pabitrakumar K Bhattacharyya), appointment of statutory auditors, and appointment of Mr. Manish Kumar Jain (DIN: 06477976) as Director and as Managing Director & CEO (special resolution). Approval for related party transactions with Ipca Laboratories Limited was passed with 95.43% support, with the promoter group abstaining from voting on this item. Out of 9,111 total shareholders on record date, 51 cast votes via remote e-voting and 6 voted at the AGM through insta poll, with promoter holding of 15,684,134 shares (about 72.7% of equity) voting in favor on most resolutions.